



Avexa Limited
ABN 53 108 150 750
Suite 8, Level 1
61-63 Camberwell Rd
Hawthorn East
Melbourne 3123

Telephone 61 3 8888 1040
Facsimile 61 3 8888 1049
Website www.avexa.com.au

Company announcement

Manufacture of ATC product for Named Patient Scheme completed successfully

Melbourne, Australia, Tuesday 9th September 2014: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that the manufacture of ATC product intended for its Early Access / Named Patient Scheme has been completed successfully, on schedule and is now ready for shipment to LINK Healthcare's facility in Singapore as soon as the necessary regulatory paperwork is complete.

LINK's facility in Singapore will act as the hub for world-wide distribution of ATC through the Early Access / Named Patient Scheme, which is expected to be operational by the end of calendar year 2014. For further information on Link Healthcare or the EAP go to: www.linkhealthcare.co

"This is a significant milestone for Avexa and ATC. Patients who are running out of options for HIV treatment, will now have access to a new agent that has activity against drug-resistant HIV and which has been demonstrated to be well tolerated." said Dr Jonathan Coates, Avexa's CSO and interim CEO. "We look forward to working with LINK Healthcare in facilitating access to ATC for those patients in need, wherever they may be."

About Avexa Limited

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialization of small molecules for the treatment of infectious diseases. Avexa's key projects include apricitabine (ATC) for the treatment of drug resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

For more information:

Mr Iain Kirkwood
Chairman
Ph: +61 408 473 496

Dr Jonathan Coates
CSO and Interim CEO
Ph: +61 3 8888 1040

www.avexa.com.au